Table 1. Phase 1/2 trials of autologous... | American Society of Hematology

Table 1.

Phase 1/2 trials of autologous CD19-targeted CAR T cells for patients with R/R ALL

Reference	No. of patients treated	CAR construct	CAR T-cell dose or dose range	CR rate, %/MRD⁻CR, %
33	16 (adults)	CD19scFv*/CD28/CD3ζ	3 × 10⁶/kg	88/75
34	30 (25 CAYA; 5 adults)	CD19scFv/4-1BB/CD3ζ	0.76 × 10⁶/kg to 20.6 × 10⁶/kg	90/78.5
35	21 (CAYA)	CD19scFv/CD28/CD3ζ	2.8 × 10⁴/kg to 2 × 10⁶/kg	70/60
36	30 (adults)	CD19scFv/4-1BB/CD3ζ	2 × 10⁵/kg to 2 × 10⁷/kg (CD4:CD8, 1:1)	97/93
25	43 (CAYA)	CD19scFv/4-1BB/CD3ζ	0.5 × 10⁶/kg to 1 × 10⁷/kg (CD4:CD8, 1:1)	93/93
9†	68 (CAYA)	CD19scFv/4-1BB/CD3ζ	0.2 × 10⁶/kg to 5.4 × 10⁶/kg	83/83

Reference	No. of patients treated	CAR construct	CAR T-cell dose or dose range	CR rate, %/MRD⁻CR, %
33	16 (adults)	CD19scFv*/CD28/CD3ζ	3 × 10⁶/kg	88/75
34	30 (25 CAYA; 5 adults)	CD19scFv/4-1BB/CD3ζ	0.76 × 10⁶/kg to 20.6 × 10⁶/kg	90/78.5
35	21 (CAYA)	CD19scFv/CD28/CD3ζ	2.8 × 10⁴/kg to 2 × 10⁶/kg	70/60
36	30 (adults)	CD19scFv/4-1BB/CD3ζ	2 × 10⁵/kg to 2 × 10⁷/kg (CD4:CD8, 1:1)	97/93
25	43 (CAYA)	CD19scFv/4-1BB/CD3ζ	0.5 × 10⁶/kg to 1 × 10⁷/kg (CD4:CD8, 1:1)	93/93
9†	68 (CAYA)	CD19scFv/4-1BB/CD3ζ	0.2 × 10⁶/kg to 5.4 × 10⁶/kg	83/83

CAYA, children and young adults; MRD, minimal residual disease.

CD19 scFv is derived from the murine monoclonal antibody (mAb) SJ25-C1; CD19 scFv in the other studies is from the murine mAb FMC-63.

Multicenter trial.